Advertisement
Research Article

A Randomised, Blinded, Placebo-Controlled Trial in Dementia Patients Continuing or Stopping Neuroleptics (The DART-AD Trial)

  • Clive Ballard mail,

    To whom correspondence should be addressed. E-mail: clive.ballard@kcl.ac.uk

    Affiliation: Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom

    X
  • Marisa Margallo Lana,

    Affiliation: Northgate Hospital, Morpeth, Northumberland, United Kingdom

    X
  • Megan Theodoulou,

    Affiliation: Department of Psychiatry, University of Oxford, The Warneford Hospital, Oxford, United Kingdom

    X
  • Simon Douglas,

    Affiliation: Department of Psychiatry, Newcastle University, Newcastle upon Tyne, United Kingdom

    X
  • Rupert McShane,

    Affiliation: Oxfordshire and Buckinghamshire Mental Health NHS Trust and University of Oxford, Department of Psychiatry, Fulbrook Centre, Oxford, United Kingdom

    X
  • Robin Jacoby,

    Affiliation: Department of Psychiatry, University of Oxford, The Warneford Hospital, Oxford, United Kingdom

    X
  • Katja Kossakowski,

    Affiliation: Wolfson Centre for Age-Related Diseases, King's College London, London, United Kingdom

    X
  • Ly-Mee Yu,

    Affiliation: Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom

    X
  • Edmund Juszczak,

    Affiliation: Centre for Statistics in Medicine, University of Oxford, Oxford, United Kingdom

    X
  • on behalf of the Investigators DART AD
  • Published: April 01, 2008
  • DOI: 10.1371/journal.pmed.0050076

Media Coverage of this Article

Found additional news media or blog coverage for the article? Please let us know.